PAS
Phase 2- Indications
- Gastric cancer, Pancreatic cancer, Colorectal cancer
Company intelligence / Profile preview
Cancer Advances, Inc.
Durham, North Carolina, USAcanceradvances.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
PAS has been studied in multiple clinical trials with over 1,500 human subjects, demonstrating excellent safety and tolerability. Clinical trials have shown PAS can increase survival times by 50% in GI clinical trials by inducing antibodies to Gastrin. Recent research shows PAS can alter the tumor microenvironment, potentially enhancing the efficacy of PD-1 Checkpoint Inhibitors by turning "cold" tumors "hot"[1][2][8].
- Therapeutic areas
- Oncology
- Modalities
- VaccinesImmunomodulators
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cancer Advances, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer Advances, Inc..